Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens?
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
This document provides an assessment of the public health risk associated with a multi-country outbreak of Salmonella Agona associated with consumption of potentially contaminated infant formula from France.
An EQA scheme for antimicrobial susceptibility testing in Neisseria gonorrhoeae has been available to laboratories participating in ECDC’s European Sexually Transmitted Infections (STI) surveillance network since 2010. This is the third EQA to be published on antimicrobial susceptibility testing in Neisseria gonorrhoeae.
Since the previous ECDC epidemiological update was published on 30 June 2017, seven EU/EEA countries (Belgium, France, Luxembourg, the Netherlands, Norway, Sweden and the United Kingdom) have reported 96 confirmed and 34 probable new cases associated with the multi-country outbreak of Salmonella Enteritidis with MLVA profiles 2-9-7-3-2 or 2-9-6-3-2 ongoing in the EU/EEA.
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) follows a decentralised and centralised testing model. In 2015, 24 EU/EEA Member States participated in Euro-GASP, 17 through decentralised testing.